POSTER SESSION III Tuesday, March 20, 2012   —  9:30 AM - 12:00 Noon CC Exhibit Hall B3 & C Click on the blue numbers in parentheses to display abstracts. Click the button next to any title to add to Itinerary Planner... GYNECOLOGIC PATHOLOGY & OBSTETRICS Poster# Title and Authors Itinerary Planner 169 Carbonic Anhydrase Type IX Expression in Lobular Endocervical Glandular Hyperplasia and Related Adenocarcinoma of the Uterine Cervix (1208) Y Mikami, S Minamiguchi, N Teramoto, M Nagura, H Haga, I Konishi - Kyoto University Graduate School of Medical Science, Kyoto, Japan; Shikoku Cancer Center, Matsuyama, Ehime, Japan Add 170 Immunohistochemical Profile of Gastric Type Endocervical Adenocarcinoma, Including HER2/Neu Status (1172) Y Karamurzin, V Parkash, T Kiyokawa, RA Soslow, KJ Park - Memorial Sloan-Kettering Cancer Center, New York, NY; Yale University School of Medicine, New Haven, CT; Chiba University School of Medicine, Chiba, Japan Add 171 Stromal Signatures in Endometrioid Endometrial Carcinomas (1126) I Espinosa, E D´Angelo, A Mozos, B Canet, L Catasus, J Prat - Hospital de la Santa Creu i Sant Pau. Institute of Biomedical Research (IIB Sant Pau). Autonomous University of Barcelona, Barcelona, Spain Add 172 MELF Pattern of Myoinvasion in Endometrioid Endometrial Adenocarcinoma Is Associated with Low-Grade Tumors, Deep Myometrial Invasion and a Low Proliferative Index (1196) JI Malowany, A Parsoei, MQ Bernardini, A Fyles, M Rouzbahman - Toronto General Hospital, Toronto, Canada; University of Toronto, Toronto, Canada Add 173 Histologic Patterns of Myometrial Invasion in FIGO Grade 2 Endometrioid Endometrial Adenocarcinoma (1187) DI Lin, WM Winham, PJ Stone, CM Quick, MR Nucci - Brigham & Women´s Hospital, Boston, MA; UAMS, Little Rock, AR Add 174 Architectural vs. Nuclear Atypia Defined FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma (EEC): A Clinicopathologic Comparison of 154 Cases (1262) W Winham, D Lin, P Stone, M Nucci, M Quick - UAMS, Little Rock, AR; Brigham and Women´s Hospital, Boston, MA Add 175 Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer (1176) H Kaur, L Eiriksson, R Saad, M Khalifa, V Dube, Z Ghorab, A Covens, L Barbera, N Ismiil - University of Toronto, Toronto, Canada Add 176 Tumor Size as a Prognostic Factor in Uterine Serous Carcinoma: A Large Multi-Institutional Study (1090) S Bandyopadhyay, KK Van de Vijver, E Oliva, MR Nucci, D Shi, F Qureshi, K Hayek, B Alosh, Z Feng, H Jaratli, D Schultz, R Ali-Fehmi - Wayne State University, Detroit, MI; Massachusetts General Hospital, Boston, MA; Henry Ford Health System, Detroit; Brigham And Women´s Hospital, Boston, MA Add 177 Endometrial Clear Cell Carcinomas with and without Aberrant p53 Expression: A Study of 16 Cases (1115) D DeLair, RA Soslow - Memorial Sloan-Kettering Cancer Center, New York, NY Add 178 Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Endometrium: Frequency and Clinicopathologic Correlation of 41 Cases (1254) KK Van de Vijver, L Liu, AJ Iafrate, E Oliva - Massachusetts General Hospital, Boston, MA Add 179 Loss of BAF250a (ARID1A) Expression in Endometrial Clear Cell Carcinoma: Assessment of Frequency and Clinicopathologic Implications (1128) O Fadare, IL Renshaw, SX Liang - Vanderbilt University, Nashville; North Shore-LIJ Health System, New York Add 180 Adequacy of Lymphadenectomy in Endometrial Cancer: A Threshold Change Is Needed (1083) G Aggarwal, A Malpica, ED Euscher, P Ramalingam - Georgia Health Sciences University, Augusta; UT MD Anderson Cancer Center, Houston Add 181 Frozen Section Does Not Reliably Predict the Likelihood of Lymph Node Involvement in Low Risk Endometrial Adenocarcinoma (1119) B Djordjevic, S El Hallani, ED Euscher, AA Roma, EJ Moschiano, R Ali-Fehmi, EE Frauenhoffer, DP Montiel, I Kim, SR Hong, D Barbuto, A Malpica, EG Silva - Multi-Institutional Study, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada Add 182 Frozen Section Results Do Not Influence the Decision To Perform Lymphadenectomy in Low Grade Endometrial Endometrioid Adenocarcinoma (1120) B Djordjevic, ED Euscher, AA Roma, EJ Moschiano, R Ali- Fehmi, EE Frauenhoffer, DP Montiel, I Kim, SR Hong, DA Barbuto, A Malpica, EG Silva - Multi-Institutional Study, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada Add 183 Number of Involved Lymphatic Vessels and Their Distance from Tumor Are Independent Prognostic Factors of Lymph Node Metastases in Low Grade Endometrial Adenocarcinoma. A Multi-Institutional Study (1231) D Perez Montiel, E Dierksen Euscher, A Roma, EJ Moschiano, R Ali-Fehmi, EF Frauenhoffer, I Kim, B Djordjevic, DA Barbuto, S Rang Hong, A Malpica, EG Silva - Instituto Nacional de Cancerologia, Mexico City, Mexico; Multi Institutional Study, Los Angeles Add 184 Detection of the JAZF1-JJAZ1 Fusion Transcript in Endometrial Biopsy Material Several Years Prior to the Clinical Presentation of Endometrial Stromal Sarcoma (1250) S Stemme, M Ghaderi, R Vaziri, JW Carlson - Karolinska University Hospital, Stockholm, Sweden Add 185 microRNA Expression Profiling of Low-Grade Endometrial Stromal Sarcomas and Undifferentiated Endometrial Sarcomas (1106) S Chiang, MA Castilla, J Palacios, E Oliva - Massachusetts General Hospital, Boston, MA; Hospital Universitario Virgen del Rocio-Instituto de Investigaciones Biomedicas, Sevilla, Spain Add 186 Proliferation in the Normal Tubal Epithelium Is a Hallmark of the Follicular Phase Not BRCA1 Mutation Status (1140) SHL George, A Milea, PA Shaw - University Health Network, University of Toronto, Toronto, Canada Add 187 PAX2-Null Secretory Cell Outgrowths (SCOUTs) in the Fallopian Tube Comprise Two Distinct Subgroups (1094) JG Bijron, CP Crum, FD McKeon, W Xian, G Ning - Brigham and Women´s Hospital, Boston, MA; Harvard Medical School, Boston, MA; Institute of Medical Biology, A*STAR, Singapore Add 188 Precise Precursor Frequency Assessment by Digital Quantification of Oviductal Epithelium (1093) JG Bijron, G Ning, AR Laury, CM Quick, NM Monte, FD McKeon, W Xian, E King, CP Crum - Brigham and Women´s Hospital, Boston, MA; Harvard Medical School, Boston, MA; UCLA Medical Center, Los Angeles, CA; University of Arkansas Medical Center, Little Rock, AR; Genome Institute, A*STAR, Singapore Add 189 P-ERM, a Marker of Cell Polarity, Distinguishes Tubal Intraepithelial Carcinoma from Benign Oviductal Mucosa (1217) G Ning, J Yuan, IY Hwang, MS Hirsch, FD McKeon, CP Crum, W Xian - Harvard Medical School, Boston, MA; Institute of Medical Biology, A*STAR, Singapore; Brigham and Women´s Hospital, Boston, MA; University of Massachusetts Medical Center, Worcester, MA Add 190 Serous Tumor of Low Malignant Potential of the Ovary – Is the 10% Cut-Off Reliable? (1234) P Ramalingam, MT Deavers, A Malpica - MD Anderson Cancer Center, Houston Add 191 Claudin-18, MUC1, MUC2, and MUC5AC Are Differentially- Expressed in Ovarian Intestinal- and Endocervical-Type Mucinous Borderline Tumors (1152) SA Halimi, D Maeda, M Fukayama - Graduate School of Medicine, the University of Tokyo, Tokyo, Japan Add 192 Loss of Ciliated Cells Correlates with Tumor Progression in Ovarian Low-Grade Serous Carcinoma (1087) L Ardighieri, RJ Kurman, I-M Shih - Johns Hopkins University, Baltimore, MD Add 193 P16 Expression in Early Müllerian Serous Carcinogenesis (1215) H Nafisi, Z Ghorab, N Ismiil, R Saad, V Dube, MA Khalifa, S Nofech-Mozes - University of Toronto, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada Add 194 Significance of Alterations of the RB1 Pathway in High Grade Serous Carcinoma (1209) A Milea, SHL George, H Berman, M Gauthier, PA Shaw - University Health Network, Toronto, Canada Add 195 IMP3, EGFR and E-Cadherin in High Grade Ovarian Serous Carcinomas To Predict Disease Progression and Survival (1227) D Patel, SK Mohanty, K Singh, C Walsh, EG Silva - Cedars-Sinai Medical Center, Los Angeles, CA; Harvard Medical School, Boston, MA Add 196 IMP3 Expression Differentiates Ovarian Serous from Endometrioid Carcinoma (1145) S Goodman, D Lu - Umass Memorial Medical Center, Worcester, MA Add 197 Oncofetal Protein IMP3, a Molecular Marker for the Malignant Progression of Ovarian Serous Neoplasm (1144) S Goodman, X Yang, D Lu - Umass Memorial Medical Center, Worcester, MA Add 198 Microcystic Stromal Tumor Is a Distinct Ovarian Neoplasm Characterized by b-Catenin Alteration (1193) D Maeda, J Shibahara, T Sakuma, K Sueyoshi, A Sakata, M Noguchi, M Fukayama - The University of Tokyo, Tokyo, Japan; Osaka Rosai Hospital, Sakai, Japan; Kagoshima Municipal Hospital, Kagoshima, Japan; The University of Tsukuba, Tsukuba, Japan Add 199 Juvenile Granulosa Cell Tumors: Immunoreactivity for CD99 and Fli-1 and EWSR1 Translocation Status. A Study of Eleven Cases (1165) EA Jarboe, LJ Layfield, ML Wallander, SR Tripp - University of Utah School of Medicine, Salt Lake City, UT; ARUP Laboratories, Salt Lake City, UT Add 200 The Role of Reticulum, Inhibin and Calretinin Staining and FOXL2 Mutational Analysis in the Diagnosis of Sarcomatoid Granulosa Cell Tumors, Cellular Fibromas and Thecomas (1131) J Felipe Lima, F Medeiros, D Bell - Mayo Clinic, Rochester, MN Add 201 FOXL2 Molecular Testing in the Diagnosis of Ovarian Neoplasms (1179) S Kommoss, M Anglesio, W Yang, W Luong, J Lorette, L Bell, S Lee, B Gilks, D Huntsman - University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada Add 202 Characterization and Comparison of Ovarian Primitive Neuroectodermal Tumors and Immature Teratomas by Immunohistochemistry and Fluorescence In-Situ Hybridization (1169) NM Joseph, MP Powers, CJ Zaloudek - UCSF, San Francisco Add 203 A Clinicopathological and Immunohistochemical Study of 54 Cases of Dysgerminoma and Gonadoblastoma (1174) AN Karnezis, JR Jalas, Y Li, Y-FC Lau, L-M Chen, TA Longacre, CJ Zaloudek - UCSF, San Francisco, CA; Veterans Affairs Medical Center, San Francisco, CA; Stanford University, Palo Alto, CA; St. John´s Health Center, Santa Monica, CA Add